{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Papillomavirus+9-valent+Vaccine%2C+Recombinant",
    "query": {
      "intervention": "Human Papillomavirus 9-valent Vaccine, Recombinant"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Papillomavirus+9-valent+Vaccine%2C+Recombinant&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T02:40:43.001Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05496231",
      "title": "A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "HPV9 High formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HPV9 Medium formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HPV9 Low formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gardasil 9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 26 Years · Female only"
      },
      "enrollment_count": 1080,
      "start_date": "2022-08-22",
      "completion_date": "2024-02-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 39,
      "location_summary": "San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05496231"
    },
    {
      "nct_id": "NCT05031078",
      "title": "Assessing Durable Antibody Response to HPV Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HPV"
      ],
      "interventions": [
        {
          "name": "Gardasil-9",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lidocaine injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-12-21",
      "completion_date": "2026-03-26",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05031078"
    },
    {
      "nct_id": "NCT05672927",
      "title": "Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Immunization",
        "HPV Infection",
        "Human Papillomavirus"
      ],
      "interventions": [
        {
          "name": "9-valent HPV vaccine, 2 doses alternate timing",
          "type": "BIOLOGICAL"
        },
        {
          "name": "9-valent HPV vaccine, 3 doses standard timing",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "27 Years to 45 Years · Female only"
      },
      "enrollment_count": 618,
      "start_date": "2023-01-18",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05672927"
    },
    {
      "nct_id": "NCT03943875",
      "title": "GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Immunization",
        "Efficacy",
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "9-valent HPV vaccine, 2 dose efficacy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "9-valent HPV vaccine, 3 doses standard timing",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "15 Years to 26 Years"
      },
      "enrollment_count": 767,
      "start_date": "2019-06-17",
      "completion_date": "2025-01-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943875"
    },
    {
      "nct_id": "NCT00798265",
      "title": "A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Human Papillomavirus- 6, 11, 16, 18",
        "Adolescent",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Gardasil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "BEHAVIORAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "12 Years to 26 Years"
      },
      "enrollment_count": 26,
      "start_date": "2009-06-29",
      "completion_date": "2013-02-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798265"
    },
    {
      "nct_id": "NCT03036930",
      "title": "Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papillomavirus Infection",
        "Human Papillomavirus-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "HPV Self-Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Human Papillomavirus Nonavalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-06-23",
      "completion_date": "2027-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036930"
    },
    {
      "nct_id": "NCT03350698",
      "title": "Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Gardasil-9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eastern Virginia Medical School",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "27 Years to 69 Years"
      },
      "enrollment_count": 100,
      "start_date": "2018-04-06",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03350698"
    },
    {
      "nct_id": "NCT05329961",
      "title": "Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "Gardasil9",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "4 Years to 8 Years"
      },
      "enrollment_count": 155,
      "start_date": "2022-09-26",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329961"
    },
    {
      "nct_id": "NCT07339163",
      "title": "Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis (RRP)"
      ],
      "interventions": [
        {
          "name": "GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-04-01",
      "completion_date": "2035-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07339163"
    },
    {
      "nct_id": "NCT02568566",
      "title": "Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papillomavirus-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Human Papillomavirus Nonavalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "9 Years to 11 Years"
      },
      "enrollment_count": 201,
      "start_date": "2016-05-19",
      "completion_date": "2027-01-10",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-12T02:40:43.001Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Los Angeles, California",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02568566"
    }
  ]
}